Navigation Links
Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
Date:10/28/2013

CRANBURY, N.J., Oct. 28, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced the successful completion of a clinical trial designed to demonstrate equivalence of subcutaneously administered bremelanotide via autoinjector compared to pre-filled syringe administration. Bioequivalence was achieved in this clinical trial. Palatin used pre-filled syringes in its Phase 2 clinical trials, but will use the single-dose disposable autoinjector in its planned Phase 3 clinical trials and for commercialization.

Stephen T. Wills, Chief Operating Officer and Chief Financial Officer of Palatin Technologies, commented, "Demonstrating bioequivalence in this study allows us to move forward with confidence regarding the delivery of bremelanotide via autoinjector. The pharmacokinetic profile of bremelanotide using the autoinjector device was consistent with the pharmacokinetic data collected in our completed positive Phase 2B study which used pre-filled syringes. The single-dose disposable autoinjector provides patients with a safe, easy to use device for the delivery of bremelanotide."

The design was a single-center, randomized, double-blind (to device administration) study in 36 healthy female subjects to determine the bioequivalence of 1.75 mg of bremelanotide administered by two different devices. There were no serious adverse events reported and there were no discontinuations in the study.

About Female Sexual Dysfunction
Female Sexual Dysfunction (FSD) covers multi-factorial conditions that have anatomical, physiological, medical, psychological and social components. FSD includes four categories: Sexual Desire Disorders (hypoactive sexual desire disorder [HSDD], sexual aversion disorder), Female Sexual Arousal Disorder (FSAD), Female Orgasmic Disorder (FOD), and Sexual Pain Disorders (dyspareunia, vaginismus). To establish a diagnosis of FSD, one or more of the
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
3. Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
5. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
6. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
7. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
8. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
9. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
10. ICU Medical, Inc. Plans to "Vigorously Seek to Collect Damages" in wake of Patent Infringement Victory Over RyMed Technologies
11. BioStorage Technologies to Lead Discussion on the Value of a Comprehensive Sample Management Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
(Date:8/29/2014)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... to the medical, research and veterinary markets, announced today ... Officer, will present at the CL King 12 th ... 9, 2014 at 12:30 p.m. ET. The conference will ... New York City . ...
(Date:8/29/2014)... , August 29, 2014 ... participate in the inaugural Tweetchat taking place in ... Worldwide , organised by UBM Live , ... #CPhIChat is a first of its kind global ... across the supply chain, aimed to stimulate conversations ...
Breaking Medicine Technology:Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3
... WIRE)--Jun 28, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) ... placebo-controlled clinical trial of,CRx-150 in patients with ... a disease-modifying anti-rheumatic drug,(DMARD) to placebo plus ... the preliminary analysis of this trial, CRx-150 ...
... percent response rate achieved with VELCADE, lenalidomide,and ... -- Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported ... trials of VELCADE based,therapies that showed consistently ... (CR) rates in newly diagnosed,multiple myeloma (MM) ...
Cached Medicine Technology:CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 2CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 3CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 4CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
(Date:8/29/2014)... 2014 Healthpointe has unveiled its new ... the convenience of visiting with physicians online. Anyone can ... , Healthpointe doctors are always available and happy to ... the doctor can even see the patient’s entire family. ... or she can prescribe medications that are available for ...
(Date:8/29/2014)... August 29, 2014 A recent article ... developed by a Tokyo clothing store for men with gynecomastia, ... of rectifying or diminishing their problem. Board-certified plastic surgeon Dr. ... the problem. While many people only associate male breasts with ... common condition among men of all ages, often starting in ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Highly regarded audiologist ... on important hearing health topics. The four reports are titled:, ... The Secrets to Hearing Aid Success , The Top ... Understanding Auditory Processing Disorder in Children , ... because there is a lot of confusion and misinformation about each ...
(Date:8/29/2014)... August 29, 2014 Healthpointe is pleased ... has joined their practice. Dr. Chuang garners extensive experience ... in minimally-invasive arthroscopic and reconstructive treatments of the knees, ... patients with general and sports-related orthopedic needs. ... medical field. As an Orange County native, he graduated ...
(Date:8/29/2014)... August 29, 2014 Carson Hearing Care ... provide hearing health care tips to local residents on ... section will offer weekly articles from the audiologists at ... including the latest advances in hearing restoration research, new ... The audiologists plan to write a new post on ...
Breaking Medicine News(10 mins):Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 3Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:Healthpointe is Honored to Induct Orthopedic Surgeon into Their Team 2Health News:Fort Worth Hearing Aid Leader, Carson Hearing Care, Creates Expert Blog to Discuss Important Hearing Healthcare Topics 2Health News:Fort Worth Hearing Aid Leader, Carson Hearing Care, Creates Expert Blog to Discuss Important Hearing Healthcare Topics 3
... Beautiful ... Smiles Curated by Gen Art, NEW YORK, April 4, ... a new generation of,smile care, Crest Whitestrips Daily Whitening + Tartar ... and protect against,tartar build-up -- Crest Whitestrips and Gen Art have ...
... Adelaide, Australia, will delve into some of the crucial issues ... to be conducted in the joint University of Adelaide/IMVS Centre ... signals in the brain and the reasons why brain tumours ... around how the brain works, and this new research will ...
... Perfect" Score by the American Correctional Association Auditors ... Earns High Praise From Board Chair Romanowicz, ... an exhaustive,three-day audit and examination by the American Correctional ... pleased to report that the Donald W. Wyatt Detention,Facility ...
... HILL, N.C., April 4, 2008 Companies align,commercial ... a,company with an annual sales volume of $10 ... assigned to the early-stage commercialization team along,with approximately ... the ratio is approximately four to three, commercial ...
... and Other Ethnic Minorities at Increased Risk, BALTIMORE, ... J.,Barthelow Classen in The Open Endocrinology Journal shows a ... following the,discontinuation of a single vaccine, a vaccine to ... is a global epidemic of type 2,diabetes and metabolic ...
... children who lead inactive lifestyles are five-to-six times more likely ... degree of danger emerging as early as their teenage years, ... of North Carolina at Chapel Hill. , The findings, published ... looked at a group of children twice first while ...
Cached Medicine News:Health News:The Quest for America's Life in Beautiful Smiles: Captured in Photography 2Health News:The Quest for America's Life in Beautiful Smiles: Captured in Photography 3Health News:Unlocking mysteries of brain cancer, stroke 2Health News:Donald W. Wyatt Detention Facility Scores 3-Year Accreditation and Among Highest Rated in the United States 2Health News:Donald W. Wyatt Detention Facility Scores 3-Year Accreditation and Among Highest Rated in the United States 3Health News:Early-stage Commercialization Success: Pharma Companies Adjust Resources in Light of Industry Changes 2Health News:Vaccine Induced Inflammation Linked to Epidemic of Type 2 Diabetes and Metabolic Syndrome 2Health News:Inactive kids face 6-fold risk of heart disease by teen years, study finds 2
300 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 250 and 300 L pipettes....
... false signals and contamination caused by ... Barrier Tips offer performance and economy ... (PCR(a)), radioactive isotopes, tissue culture fluids, ... , ,Promega Barrier Tips are made ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... Filters are ideal for PCR ... for any work where aerosol ... designed for pipetting DNA/RNA solutions, ... other. For applications requiring absolute ...
Medicine Products: